A monitor is only as good as its account of what it is watching. This one names every source it checks, what that body actually controls, what a change there would mean, and — the part monitors usually omit — the things it cannot see at all.
Decision boundary. Verified source endpoints establish where this monitor looks. Discovered items remain unreviewed candidates until a person confirms the document, its date, its jurisdiction and its operational consequence. This is not legal advice.
Checking when this last collected…
—Loading source health
What it means when this page is empty
An automated sweep that finds nothing produces the most dangerous artefact in monitoring: a page that looks calm. This section exists so that calm is never mistaken for coverage.
A quiet sweep can mean any of five different things, and from the outside they are indistinguishable:
Nothing was published. The only one of the five that would justify reassurance.
Something was published and the search did not surface it. Discovery is a query against an index, and an index is neither complete nor instantaneous.
Something was published in a form the policy filters out. A rule change announced only in a meeting agenda PDF on an allowed host may carry none of the required terms.
Something changed without being published at all. A licensing pause, a staffing change, an internal interpretation: real, consequential, and invisible to any URL-based watcher.
The sweep did not run. Which is why the banner above reports the last successful collection separately from the last attempt, and says so in words rather than showing a green light.
The correct use of this page is therefore not to read the absence of findings as an all-clear. It is to use the verified endpoints below as your starting list, and to go and look. That is also why every discovered item is labelled as an unreviewed candidate rather than as news: a search result is a lead, and a lead that has not been opened by a person establishes nothing.
The source registry
Six endpoints, in three classes. The class matters more than it looks: an official state portal and an industry newsletter can both publish the same fact, but only one of them is the fact. Each profile below states what the body controls, what appears there, what a change would mean operationally, and where its blind spots are.
or · official state programme
Oregon — Oregon Psilocybin Services, Oregon Health Authority
Oregon Health Authority · verified 17 August 2026 · read again 29 August 2026
What this body is
Oregon Psilocybin Services is a section inside the Oregon Health Authority’s Public Health Division, Center for Health Protection. It is not an advisory body and not a trade association: it issues the licences.
What it controls
It implements Ballot Measure 109, passed in November 2020 and codified as ORS 475A, which directs the Authority to license and regulate the manufacture, transport, delivery, sale and purchase of psilocybin products and the provision of psilocybin services. Licensing applications opened on 2 January 2023 and the first service centres opened to clients in the summer of 2023 — so unlike the other two states in this registry, Oregon is a programme with an operating history rather than a rulemaking calendar.
What appears here
Programme news, annual reports, quarterly newsletters, a data dashboard, and a licensee directory limited to those licensees who consented to be listed publicly.
Why a change here matters
This is the oldest regulated market of its kind, which makes it the field’s reference implementation. A rule or fee change in Oregon is read across the country as a precedent, and anyone operating in Colorado or New Mexico will see the argument arrive there within a cycle.
What this monitor cannot see
The licensee directory is opt-in, so it is a floor on the number of operating licensees and never a census. Individual licensing actions, inspections and enforcement do not appear on this portal at all. And each licensed service centre manages its own operations and client communication, so the state page is silent about the thing most people actually want to know.
co · official state programme
Colorado — Natural Medicine Program, Division of Professions and Occupations
Colorado Division of Professions and Occupations · verified 17 August 2026 · read again 29 August 2026
What this body is
The Division of Professions and Occupations, inside the Department of Regulatory Agencies, running the Natural Medicine Program under a named programme director. Colorado splits the work: this Division credentials the people, while a separate Natural Medicine Division at the Department of Revenue handles the product side, and CDPHE runs inspection and certification.
What it controls
Licensure and discipline for Natural Medicine Facilitators and Clinical Facilitators, the rules that govern them, continuing-education requirements, and the public licensee lookup and discipline list. The programme sits under the Natural Medicine Health Act, passed by voters in 2022 as Proposition 122.
What appears here
Public notices, draft rules, stakeholder-meeting materials and recordings, Natural Medicine Advisory Board minutes, and the licensing forms. As of this reading, the most recent public notice was a stakeholder meeting on 20 August 2026 on proposed revisions to Rule 5.4, the continuing-education requirements for facilitators and clinical facilitators.
Why a change here matters
Colorado publishes its rulemaking in the open, with draft rules, written comment and recordings posted before adoption. That makes this the one endpoint in the registry where a practitioner can see a change coming rather than learn about it after the fact — and it makes a quiet week here genuinely informative in a way a quiet week elsewhere is not.
What this monitor cannot see
The split architecture is the blind spot. Watching this page catches nothing that happens at the Department of Revenue’s Natural Medicine Division or at CDPHE, and a licensee whose product supply or facility certification changes will feel it exactly as much as a rule change here.
nm · official state programme
New Mexico — Medical Psilocybin Program, Department of Health
New Mexico Department of Health · verified 17 August 2026 · read again 29 August 2026
What this body is
The Department of Health’s Center for Medical Cannabis and Psilocybin, standing up a programme that does not yet exist operationally. Alone among the three states here, New Mexico is pre-launch — which changes what the page is for.
What it controls
Implementation of Senate Bill 219, the Medical Psilocybin Act, signed by Governor Michelle Lujan Grisham in April 2025 and effective 20 June 2025. The Act establishes a regulated programme for medical psilocybin use for qualified conditions — the Department names major treatment-resistant depression, PTSD, substance use disorders and end-of-life care — with implementation set for 31 December 2026. A Medical Psilocybin Advisory Board assists the Department.
What appears here
Rulemaking notices, advisory-board information, statutes and regulations, a patient-facing FAQ in English and Spanish, and announcements about public hearings and consultations.
Why a change here matters
This is the only jurisdiction in the registry with a statutory deadline attached to it. The distance between the Department’s published progress and 31 December 2026 is itself the signal: it is the one place where the absence of an update is substantive news rather than background quiet.
What this monitor cannot see
A programme in rulemaking generates most of its consequential decisions in advisory-board discussion, draft protocols, training requirements and data-collection design — much of which surfaces at hearings before it surfaces on a web page, if it surfaces at all. Nothing about the medical-cannabis side of the same Center is captured here either, despite the shared administrative home.
Psychedelic Alpha · verified 17 August 2026 · read again 29 August 2026
What this body is
An independent trade publication covering the development, regulation and commercialisation of psychedelic medicines, with a stated mission of bringing clarity, rigour and context to the field. It runs a free stream of analysis and interviews alongside a premium subscription and advisory services. The other two allowed hosts are law-firm publications.
What it controls
Nothing. That is the point of the class distinction. This endpoint controls no licence, issues no rule and binds no one; it reports, aggregates and interprets. Its recent output is representative — clinical-trial readouts, an agency request-for-information, a company financing — none of which is a regulatory act.
What appears here
Analysis, interviews and scoops, typically ahead of official confirmation and often about things no official portal will ever mention: financings, personnel moves, trial results and the internal politics of the field.
Why a change here matters
Speed. A secondary source will usually carry a development first, which makes this class useful as an early warning and useless as an authority. The correct workflow is to treat an item here as a prompt to check the relevant official endpoint, never as a substitute for having checked it.
What this monitor cannot see, and what to distrust
Two law firms are among the allowed hosts, and law-firm commentary is written partly to demonstrate expertise to prospective clients. It is frequently excellent and it is never disinterested. Some of the publication’s substantive work also sits behind a paid tier this monitor does not reach, so what surfaces here is the free surface of a larger body of reporting.
Psychedelic Science Funders Collaborative · verified 17 August 2026 · read again 29 August 2026
What this body is
A membership community of philanthropists, founded in 2017, that coordinates giving into the psychedelic field. It states plainly that it is not a foundation and not a grantmaker: it supports members in directing their own resources, with staff providing field knowledge, due diligence and strategic guidance.
What it controls
No rule and no licence — but money, indirectly, which in a field this dependent on philanthropy is a form of control that no state portal reports. Where coordinated funders decide the gap is determines which organisations exist in eighteen months.
What appears here
A quarterly newsletter, issue briefs, and membership and event information. This is deliberately low-volume; it is a community page, not a newsroom.
Why a change here matters
It is a leading indicator on the funding side. A shift in stated priorities here precedes the organisational changes that eventually become visible as new programmes, new advocacy campaigns, or organisations quietly closing.
What this monitor cannot see
Nearly everything that matters. Grant decisions, member identities, the listserv and the pulse calls are all member-facing. What is public is the framing, not the flow of funds. Treat any signal from this endpoint as directional at best.
Healing Advocacy Fund · verified 17 August 2026 · read again 29 August 2026
What this body is
A 501(c)(3) non-profit whose stated purpose is to expand and protect safe, affordable, state-regulated access to psychedelic healing. Its work is concentrated on the two states that have operating or launching programmes: Oregon, where voters approved the first psilocybin therapy programme in 2020 and it launched in 2023, and Colorado, under Proposition 122 and the Natural Medicine Health Act.
What it controls
No rule and no licence. It is an advocacy organisation, and its published material is written to advance a position — which is a reason to read it, and a reason never to cite it as a finding.
What appears here
State-programme explainers, implementation-priority updates, research summaries, and a newsletter focused on Oregon psilocybin services.
Why a change here matters
Advocacy organisations tend to publish about a rule change before a state agency finalises one, because affecting the outcome is the objective. Movement here is often the earliest visible sign that something is being contested — the contest itself, not its result.
What this monitor cannot see, and what to distrust
An advocacy organisation reports the developments that support its position; silence here is not evidence that nothing happened. Its characterisation of clinical evidence is a summary written for persuasion, and any claim about efficacy taken from this endpoint should be traced to the underlying study before it is repeated.